Topical Docetaxel Enters Development for Extramammary Paget's Disease
Palvella unveils QTORIN docetaxel, a topical formulation for extramammary Paget's disease — a cancer with no FDA-approved therapies and over 10,000 US patients. Phase 2 planned after a 2027 FDA meeti…
